+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Escherichia Coli Infections - Pipeline Review, H1 2015

  • ID: 3334692
  • Report
  • June 2015
  • 156 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Adenium Biotech ApS
  • Cellceutix Corporation
  • GangaGen Inc.
  • Melinta Therapeutics, Inc
  • Northern Antibiotics Oy
  • Procarta Biosystems Ltd
  • MORE
Escherichia Coli Infections - Pipeline Review, H1 2015

Summary

This, ‘Escherichia Coli Infections - Pipeline Review, H1 2015’, provides an overview of the Escherichia Coli Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Escherichia Coli Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Escherichia Coli Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Escherichia Coli Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Escherichia Coli Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Escherichia Coli Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Escherichia Coli Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Adenium Biotech ApS
  • Cellceutix Corporation
  • GangaGen Inc.
  • Melinta Therapeutics, Inc
  • Northern Antibiotics Oy
  • Procarta Biosystems Ltd
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Escherichia Coli Infections Overview
Therapeutics Development
Pipeline Products for Escherichia Coli Infections - Overview
Pipeline Products for Escherichia Coli Infections - Comparative Analysis
Escherichia Coli Infections - Therapeutics under Development by Companies
Escherichia Coli Infections - Therapeutics under Investigation by Universities/Institutes
Escherichia Coli Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Escherichia Coli Infections - Products under Development by Companies
Escherichia Coli Infections - Products under Investigation by Universities/Institutes
Escherichia Coli Infections - Companies Involved in Therapeutics Development
Adenium Biotech ApS
Arsanis Biosciences GmbH
AvidBiotics Corp.
Bellus Health Inc.
Bioorganic Research and Services S.A.
Cellceutix Corporation
Chiesi Farmaceutici SpA
ConjuGon, Inc.
Debiopharm International S.A.
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
GangaGen Inc.
Genentech, Inc.
GlaxoSmithKline Plc
Immuron Limited
Melinta Therapeutics, Inc
Microbiotix, Inc.
Mucosis B.V.
Nabriva Therapeutics AG
Navigen Pharmaceuticals, Inc.
Northern Antibiotics Oy
Nosopharm SAS
NovaBay Pharmaceuticals, Inc.
Novabiotics Limited
Nymox Pharmaceutical Corporation
Pherecydes Pharma SA
Phico Therapeutics Limited
Procarta Biosystems Ltd
Sanofi Pasteur SA
Sealife PHARMA GMBH
Sequoia Sciences, Inc.
Soligenix, Inc.
Spider Biotech
Syntiron LLC
Trana Discovery, Inc.
Escherichia Coli Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-3APO - Drug Profile
AA-139 - Drug Profile
ACE-920 - Drug Profile
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile
BNT-006 - Drug Profile
BXN-112 - Drug Profile
Debio-1454 - Drug Profile
Drug for Infectious Diseases - Drug Profile
Drugs for Bacterial Infections - Drug Profile
dusquetide - Drug Profile
EcoXyn-4V - Drug Profile
enterotoxigenic escherichia coli vaccine - Drug Profile
enterotoxigenic escherichia coli vaccine - Drug Profile
Escherichia coli (whole cell) vaccine - Drug Profile
Escherichia coli vaccine - Drug Profile
ETEC Adhesin-Based Vaccine - Drug Profile
ETEC Vaccine - Drug Profile
EV-035 - Drug Profile
extraintestinal pathogenic escherichia coli vaccine - Drug Profile
GN snare - Drug Profile
GN-4474 - Drug Profile
IMM-363 - Drug Profile
INX-201 - Drug Profile
MBX-2319 - Drug Profile
MDN-0057 - Drug Profile
Monoclonal Antibodies for Escherichia Coli Infections - Drug Profile
NAB-7061 - Drug Profile
NAB-739 - Drug Profile
NAB-741 - Drug Profile
NOSO-95300 - Drug Profile
NP-432 - Drug Profile
NVC-727 - Drug Profile
NXC-4720 - Drug Profile
PMX-1278 - Drug Profile
PMX-1363 - Drug Profile
PMX-1405 - Drug Profile
PMX-247 - Drug Profile
PP-0121 - Drug Profile
pritoxaximab + setoxaximab - Drug Profile
Proteins for Infectious Diseases - Drug Profile
PT-4 - Drug Profile
Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections - Drug Profile
RX-05 - Drug Profile
RXP-873 - Drug Profile
SB-041 - Drug Profile
Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - Drug Profile
Shigetec - Drug Profile
SLP-0901 - Drug Profile
SLP-0905 - Drug Profile
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile
Small Molecule to Inhibit Rns and VirF for Bacterial Infections - Drug Profile
Small Molecules for Bacterial Infections - Drug Profile
Small Molecules for Bacterial Infections - Drug Profile
Small Molecules for Escherichia Coli Infections - Drug Profile
Small Molecules for Escherichia coli Infections - Drug Profile
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile
Small Molecules to Inhibit 30S RNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile
Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile
Synthetic Peptides for Escherichia Coli Infections - Drug Profile
Escherichia Coli Infections - Recent Pipeline Updates
Escherichia Coli Infections - Dormant Projects
Escherichia Coli Infections - Discontinued Products
Escherichia Coli Infections - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Escherichia Coli Infections, H1 2015
Number of Products under Development for Escherichia Coli Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Escherichia Coli Infections - Pipeline by Adenium Biotech ApS, H1 2015
Escherichia Coli Infections - Pipeline by Arsanis Biosciences GmbH, H1 2015
Escherichia Coli Infections - Pipeline by AvidBiotics Corp., H1 2015
Escherichia Coli Infections - Pipeline by Bellus Health Inc., H1 2015
Escherichia Coli Infections - Pipeline by Bioorganic Research and Services S.A., H1 2015
Escherichia Coli Infections - Pipeline by Cellceutix Corporation, H1 2015
Escherichia Coli Infections - Pipeline by Chiesi Farmaceutici SpA, H1 2015
Escherichia Coli Infections - Pipeline by ConjuGon, Inc., H1 2015
Escherichia Coli Infections - Pipeline by Debiopharm International S.A., H1 2015
Escherichia Coli Infections - Pipeline by Emergent BioSolutions Inc., H1 2015
Escherichia Coli Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Escherichia Coli Infections - Pipeline by GangaGen Inc., H1 2015
Escherichia Coli Infections - Pipeline by Genentech, Inc., H1 2015
Escherichia Coli Infections - Pipeline by GlaxoSmithKline Plc, H1 2015
Escherichia Coli Infections - Pipeline by Immuron Limited, H1 2015
Escherichia Coli Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015
Escherichia Coli Infections - Pipeline by Microbiotix, Inc., H1 2015
Escherichia Coli Infections - Pipeline by Mucosis B.V., H1 2015
Escherichia Coli Infections - Pipeline by Nabriva Therapeutics AG, H1 2015
Escherichia Coli Infections - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015
Escherichia Coli Infections - Pipeline by Northern Antibiotics Oy, H1 2015
Escherichia Coli Infections - Pipeline by Nosopharm SAS, H1 2015
Escherichia Coli Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015
Escherichia Coli Infections - Pipeline by Novabiotics Limited, H1 2015
Escherichia Coli Infections - Pipeline by Nymox Pharmaceutical Corporation, H1 2015
Escherichia Coli Infections - Pipeline by Pherecydes Pharma SA, H1 2015
Escherichia Coli Infections - Pipeline by Phico Therapeutics Limited, H1 2015
Escherichia Coli Infections - Pipeline by Procarta Biosystems Ltd, H1 2015
Escherichia Coli Infections - Pipeline by Sanofi Pasteur SA, H1 2015
Escherichia Coli Infections - Pipeline by Sealife PHARMA GMBH, H1 2015
Escherichia Coli Infections - Pipeline by Sequoia Sciences, Inc., H1 2015
Escherichia Coli Infections - Pipeline by Soligenix, Inc., H1 2015
Escherichia Coli Infections - Pipeline by Spider Biotech, H1 2015
Escherichia Coli Infections - Pipeline by Syntiron LLC, H1 2015
Escherichia Coli Infections - Pipeline by Trana Discovery, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Escherichia Coli Infections Therapeutics - Recent Pipeline Updates, H1 2015
Escherichia Coli Infections - Dormant Projects, H1 2015
Escherichia Coli Infections - Dormant Projects (Contd..1), H1 2015
Escherichia Coli Infections - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Escherichia Coli Infections, H1 2015
Number of Products under Development for Escherichia Coli Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
Adenium Biotech ApS
Arsanis Biosciences GmbH
AvidBiotics Corp.
Bellus Health Inc.
Bioorganic Research and Services S.A.
Cellceutix Corporation
Chiesi Farmaceutici SpA
ConjuGon, Inc.
Debiopharm International S.A.
Emergent BioSolutions Inc.
F. Hoffmann-La Roche Ltd.
GangaGen Inc.
Genentech, Inc.
GlaxoSmithKline Plc
Immuron Limited
Melinta Therapeutics, Inc
Microbiotix, Inc.
Mucosis B.V.
Nabriva Therapeutics AG
Navigen Pharmaceuticals, Inc.
Northern Antibiotics Oy
Nosopharm SAS
NovaBay Pharmaceuticals, Inc.
Novabiotics Limited
Nymox Pharmaceutical Corporation
Pherecydes Pharma SA
Phico Therapeutics Limited
Procarta Biosystems Ltd
Sanofi Pasteur SA
Sealife PHARMA GMBH
Sequoia Sciences, Inc.
Soligenix, Inc.
Spider Biotech
Syntiron LLC
Trana Discovery, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll